This guideline specifies the requirements for advertisement of medical devices that require approval and no approval required.
The following materials are controlled through self-regulation, and shall comply with the requirements of
This guideline specifies the requirements for advertisement of medical devices that require approval and no approval required.
The following materials are controlled through self-regulation, and shall comply with the requirements of
The Philippines FDA, in its commitment to provide stakeholders with streamlined and improved government services, is developing the FDA eServices Portal System – an online platform for FDA marketing authorization
TGA has issued version 2.0 of Clinical evidence guidelines: Medical devices in March 2021 to update the section on Comparable devices including substantially equivalent devices.
The first step in the comparability
5 documents have been released by the Ministry of Public Health and Thai FDA regarding revised reporting of device defects, Adverse Events Occurred to Consumers, and FSCA of Medical Devices.
On 22nd March 2021, Taiwan FDA announced a plan on pilot testing of eCTD submission.
To ensure that the eCTD submission platform functions smoothly, Taiwan FDA will conduct pilot testing
As part of the aim to facilitate the efficient development and timely registration of beneficial innovative therapeutic products (chemical and biologic compounds) and cell, tissue or gene therapy products (CTGTPs)
On 25th February 2021, the Medical Devices Branch (MDB) has introduced a new self-help tool to guide in grouping of medical devices for purposes of premarket registration. This medical device grouping tool will
New regulations came into effect on 15 February 2021 to harmonise Thailand’s Medical Device Act with the ASEAN Medical Device Directive.
In the past, a majority of the medical device are under the
The Ministry of Health Vietnam has issued on 03 February 2021, Official letter No. 777/QLD-DK regarding implementation of online system to maintain the validity of drug licences.
The Drug Administration of